Expand Your Cell-based Assays With an Unlimited, Biologically Relevant ResourceJun 04, 2020 at 12:00 PM ET
Toxicology and cancer researchers alike are challenged by the lack of a consistent source of cells with high physiological relevance for their cell-based assays. The source tissue for primary cells comes from a variety of donors, which can introduce interexperimental variability and confound experimental results. Differentiated induced pluripotent stem cell (iPSC)-derived cells fulfill the need for a consistent source of cells and physiological relevance. iPSCs are able to be generated in large cell numbers from a single clone, providing the needed consistency. Further, iPSCs can be differentiated into a variety of desired, functional cell types, affording the necessary biological relevance. Here we provide data demonstrating how differentiated iPSC-derived cells can be incorporated into immunoassays or further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.
- Differentiated iPSCs lend the ability to run large toxicity studies and drug screens on highly biologically relevant cells.
- ATCC iPSCs were used as the source for three types of differentiated cells: CD34+ progenitors, mesenchymal stem cells (MSCs), and monocytes.
- ATCC R&D scientists have generated in-depth data showing the iPSC-derived cells can be incorporated into immunoassays and further differentiated into cell types such as osteocytes, chondrocytes, and adipocytes.
Watch The Presentation
Brian Shapiro, PhD
Scientific Content Specialist, ATCC
Brian A Shapiro, PhD, works to communicate the scientific breakthroughs of ATCC’s product development laboratories to the biomedical research community. Previously, he worked at Virginia Commonwealth University, where he investigated the role of pre-mRNA splicing in the multi-drug resistance of lung cancer. Dr. Shapiro attended the Medical College of Georgia, where his research focused on adrenal physiology as well as diseases of the epidermis.